Noncardiogenic Pulmonary Edema: An Unusual and Serious Complication of Anticancer Therapy
- 1 April 2001
- journal article
- review article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 6 (2) , 153-161
Abstract
Noncardiogenic pulmonary edema (NCPE) is a rare and less well-recognizable pulmonotoxic syndrome of anticancer therapy than pneumonitis/fibrosis. NCPE is a clinical syndrome characterized by simultaneous presence of severe hypoxemia, bilateral alveolar infiltrates on chest radiograph, and no evidence of left atrial hypertension/congestive heart failure. The diagnosis of drug-related NCPE relies upon documented exclusion of any infectious, metabolic, or cancer-related causes. The time proximity to therapy with drugs that are known to precipitate NCPE, any preceding episodes of flu-like symptoms during previous chemotherapy courses and possible response to corticosteroids may further support such a diagnosis. Cancer therapeutic agents clearly associated with NCPE are cytarabine, gemcitabine, and interleukin-2, as well as all-trans retinoic acid in acute promyelocytic leukemia patients, while a few other compounds have rarely or occasionally been implicated. The pathophysiology of lung injury in drug-induced NCPE remains unclear. There are indications suggesting that both a direct cytotoxic insult to the lung epithelial cells and induction of a cytokine-triggered inflammatory response may be involved in its pathogenesis. By distinction to drug-induced pulmonary pneumonitis that may lead to permanent pulmonary fibrosis, NCPE if not fatal, can be reversed upon prompt recognition, following immediate discontinuation of the offensive drug and start of intensive supportive treatment and intravenous corticosteroids.Keywords
This publication has 83 references indexed in Scilit:
- Induction of tumor necrosis factor-? as a cause of bleomycin-related toxicityCancer, 1998
- Effects of Route and Formulation on Clinical Pharmacokinetics of Interleukin-2Clinical Pharmacokinetics, 1994
- Activity and unexpected lung toxicity of the sequential administration of two alkylating agents—Dacarbazine and fotemustine—in patients with melanomaEuropean Journal of Cancer, 1993
- Clinical Toxicity of Interleukin-2Drug Safety, 1992
- Involvement of Thromboxane and Neutrophils in Multiple-system Organ Edema with Interleukin-2Annals of Surgery, 1990
- Capillary leak syndrome during low dose granulocyte-macrophage colony-stimulating factor (rh GM-CSF) treatment of a patient in a continuous febrile stateAnnals of Hematology, 1990
- The Toxicity of CytarabineDrug Safety, 1990
- Nitrosourea derivatives-induced pulmonary toxicity in patients treated for malignant brain tumors. Early subclinical detection and its preventionEuropean Journal of Cancer and Clinical Oncology, 1987
- Subacute pulmonary failure complicating therapy with high-dose ara-C in acute leukemiaCancer, 1985
- Ultrastructure of the Microvessels in Skeletal Muscle in a Case of Systemic Capillary Leak SyndromeActa Medica Scandinavica, 1979